Resonance Health (ASX: RHT) Posts 42% Revenue Surge in FY2026 With Positive EBITDA and Robust Pipeline

The Quick Take

• Resonance Health (ASX: RHT) revenue surged 42% in FY2026, marking a record top-line result driven by growing adoption of its liver assessment platform.
• The company achieved positive EBITDA for the first time in FY2026, a significant profitability milestone for the health-tech company.
• A robust commercial pipeline signals continued revenue growth as liver disease diagnostics gain clinical acceptance in key markets.

Resonance Health Ltd, the Perth-based health technology company specializing in non-invasive liver disease assessment, delivered a milestone FY2026 result with 42% revenue growth to a record level alongside positive EBITDA — marking the first time the company has achieved operating profitability. Resonance Health's core product, FerriScan, is a non-invasive MRI-based technology for measuring liver iron concentration, which is critical for managing chronic diseases including hereditary hemochromatosis and transfusion-dependent anemias. The company's commercial traction reflects the broader shift in clinical practice toward non-invasive diagnostic modalities that avoid the risks and costs of liver biopsy. The 42% revenue growth rate is exceptional for a medical technology company of this size and suggests meaningful expansion in both the installed base of MRI centers using FerriScan and the volume of assessments per center.

The positive EBITDA achievement is the most significant financial milestone in this result. For a health-technology company at Resonance Health's stage — moving from product development and early commercialization into scaled revenue growth — the shift to EBITDA positive is the inflection point that attracts institutional investors who previously avoided the pre-profitability risk. The company's cost structure, once designed for a lower revenue base, now generates operating leverage as incremental revenue at its existing technology infrastructure flows through with high margins. The robust commercial pipeline cited in the result — if materializing in FY2027 — suggests the current growth trajectory can be sustained rather than representing a one-time acceleration.

The critical forward signal for RHT is the FY2027 revenue guidance or indicative pipeline conversion rate from the commercial pipeline cited in the FY2026 result. Watch for announcements of new hospital or imaging center partnerships in North America, Europe, or Asia — these represent the geographic expansion that could sustain 30-40% revenue growth rates. The liver disease diagnostics market is growing as awareness of non-alcoholic fatty liver disease (NAFLD) and metabolic-associated steatotic liver disease (MASLD) increases globally. Any partnership announcement with a major diagnostic imaging network would be a material positive catalyst for RHT's next growth phase.

Synthesized from 1 source.